Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash & Equivalents (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Cash & Equivalents for 12 consecutive years, with $19.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 2.62% year-over-year to $19.0 million, compared with a TTM value of $19.0 million through Sep 2025, down 2.62%, and an annual FY2024 reading of $10.6 million, down 53.03% over the prior year.
  • Cash & Equivalents was $19.0 million for Q3 2025 at Lisata Therapeutics, up from $12.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $32.4 million in Q3 2023 and bottomed at $10.6 million in Q4 2024.
  • Average Cash & Equivalents over 3 years is $21.4 million, with a median of $21.8 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents rose 19.43% in 2024, then tumbled 57.17% in 2025.
  • Year by year, Cash & Equivalents stood at $22.6 million in 2023, then tumbled by 53.03% to $10.6 million in 2024, then soared by 79.01% to $19.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for LSTA at $19.0 million in Q3 2025, $12.1 million in Q2 2025, and $17.4 million in Q1 2025.